We uncovered a novel mechanism of tumor escape from ILC2-mediated immune surveillance, providing further rationale for the clinical employment of anti-TIGIT mAb in the treatment of these pts, and, potentially, in the earlier stages of MM too, with the aim of slowing down disease progression. The gene discussed is TIGIT; the disease is Miyoshi myopathy.